Objectively measured physical activity during chemotherapy in colon cancer patients

Hyuna Park, Minkyu Jung, Min Jae Kim, Jihee Min, Choong Kun Lee, Sang Joon Shin, Seung Hoon Beom, Joong Bae Ahn, Justin Y. Jeon

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Purpose: Although adjuvant chemotherapy can have an impact on physical activity (PA), PA level has not been studied in patients with stage II–III colon cancer. This study investigated PA levels during and between chemotherapy cycles. Methods: We objectively measured PA levels for 2 weeks during the 2nd and 11th chemotherapy cycles. In addition, self-reported PA levels were assessed before chemotherapy initiation, during 2nd, 6th, and 12th chemotherapy cycles. This study included 22 men and 33 women with stage II–III colon cancer patients (57 ± 9 years). Results: Before the initiation of chemotherapy, most cancer patients were minimally active. Compared with the 1st week of chemotherapy, moderate- and light-intensity PA levels significantly increased during the 2nd week of chemotherapy. Patients increased moderate- and light-intensity PA from 217.4 to 290.3 min per week and from 585.7 to 657.8 min per week, respectively (p < 0.01). PA levels did not show any difference between the 2nd and 12th cycles when objectively measured, or between baseline and 2nd, 6th, and 12th cycles when self-reported. Conclusion: PA levels during chemotherapy cycles are initially low, and then increase towards the end of the cycle; however, PA levels do not change between chemotherapy cycles. Future work with broader and larger samples size is recommended.

Original languageEnglish
Pages (from-to)2597-2604
Number of pages8
JournalSupportive Care in Cancer
Issue number6
Publication statusPublished - 2020 Jun 1

Bibliographical note

Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Objectively measured physical activity during chemotherapy in colon cancer patients'. Together they form a unique fingerprint.

Cite this